Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Dosing Strategies for Weight Loss in Overweight and Obese Patients
NCT05616052Phase 4Unknown
- Sponsor
- Huashan Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, Overweight, sponsored by Huashan Hospital. Status: unknown.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05616052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616052.